Keynote speaker  

Professor Sir David Lane

Keynote lecture
  Drug discovery in the p53 pathway
See Abstract
Professor Sir David Philip Lane is one of the world leading scientists in the field of molecular oncology. He has published more than 350 research articles and is amongst the most cited scientists in all fields. 

Professor Lane has worked in Imperial Cancer Research Fund (ICRF) in London, Cold Spring Harbor Laboratory in New York,  Imperial College, London, before moving in 1990 to the University of Dundee. He was also Chief Scientist of Cancer Research UK and the Executive Director of the Institute of Molecular & Cell Biology (IMB) in Singapore and Scientific Director of Ludwig Cancer Research. He is currently Chief Scientist of the Agency for Science, Technology and Research (A*STAR) in Singapore.
Professor  Lane has experience in the successful translation of research for patient benefit. He founded the Dundee-based Biotechnology company, Cyclacel Ltd and was the Chief Scientific Officer. Currently he is Chairman of Chugai Pharmabody.

Sir David is a member of EMBO, and a Fellow of the Royal Society. He is also a Fellow of the Royal Society of Edinburgh, the Royal College of Pathologists, the Bulgarian National Academy of Medicine and a founder member of the Academy of Medical Science. He has won many international prizes including Meyenburg Prize, the Yvette Mayent Prize, the International Agency for Research on Cancer (IARC) Medal, the Sergio Lombroso Award in Cancer Research, the RSE Royal Medal and the INSERM Award. In 1998 Professor David Lane received the prestigious Paul Ehrlich Prize, often referred to as the small Nobel Prize. 
Professor Sir David Lane with the Cancer Research UK Lifetime Achievement in Cancer Research Prize, Liverpool, UK
  (From: Bringing together all aspects of cancer research, prevention and treatment. A report from the 8th NCRI Cancer Conference. BioDiscovery 6: e8937 )  

Professor Sir David Lane enjoying a pint in Ship Inn, Elie, Scotland
 (From: Man of Science: Celebrating Professor Sir David Lane’s 60th anniversary. BioDiscovery 1: e8921 )
Targeting p53 in cancer therapy: reality or fantasy
Sir David Lane FRS , Chief Scientist, A*Star Singapore
Mutations in p53 are the most common specific genetic defect found in human cancer. Germ line mutations in p53 result in greatly enhanced familial susceptibility to a wide range of cancers supporting p53’s role as a tumor suppressor. In model systems p53 activation by radiation and chemotherapy can be shown to trigger cancer cell death or senescence and in general p53 wild type tumors are less aggressive, less invasive and less genetically unstable than p53 mutant tumors. The high level of mutant p53 proteins found in many human cancers suggests a gain of function of the mutant protein that converts it from a tumor suppressor to an oncogene.  In animal models reactivation of p53 in tumors has profound therapeutic effects but how can p53 be targeted for cancer therapy?
In one approach small molecules or peptides that block the p53 Mdm2 interaction can induce the p53 response in the absence of DNA damage and are highly effective in pre clinical models. These molecules are progressing slowly in the clinic. In another approach molecules that bind to mutant p53 and rescue its wild type activity are also in trial. New approaches of synthetic lethality and down regulation of expression of oncogenic mutant p53 proteins are also showing pre clinical promise so though no truly ground breaking clinical applications for p53 based therapy have yet been described work continues with great enthusiasm.